biostudies-literatureUnknown6(1)Limbrick-Oldfield EH<h4>Introduction</h4>Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.<h4>Methods</h4>We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT.<h4>Results</h4>Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictivEJHaeme1104https://www.ebi.ac.uk/biostudies/studies/S-EPMC11800366biostudies-literatureThe prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.PMC11800366Palivela MGribben JGLimbrick-Oldfield EHBeygi SRay MDGhione PPatel ARBest TKanters SfalseThe prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.<h4>Introduction</h4>Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.<h4>Methods</h4>We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT.<h4>Results</h4>Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictiv2025-01-01T00:00:00Z2025 Feb2025-04-05T00:00:27.786Z2025-04-05T00:00:27.786ZS-EPMC118003663991735610.1002/jha2.1104